drugset / Trial / NCT01297855
Colistin Plus Rifampicin in MDR P. Aeruginosa and A. Baumanii
RandomizedParallel-groupOpen-labelTreatment
Summary
In Siriraj Hospital, Colistin alone for treatment of MDR. A.baumanii or P.aeruginosa contributed to mortality 45%. In vitro studies revealed synergism of Rifampicin and Colistin. In this study, patients with documented MDR. P.aeruginosa or A.baumanii will be allocated to receive Colistin alone and another group will receive Colistin plus Rifampicin.
Timeline
- Start
- 2010-06
- Primary completion
- 2012-05
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifampin | Small molecule | 10 mg/kg | — |
| Comparator | Colistin | Other / unclassified | 2.5 mg/kg | — |
| Comparator | Colistin | Other / unclassified | 5 mg/kg | — |
Indications
No indication recorded.